论文部分内容阅读
目的探讨孟鲁司特联合舒利迭对哮喘急性发作期患者疗效及免疫功能的影响。方法 2012年1月至2014年1月选取在本院收治的120例哮喘急性发作期患者为研究对象,根据随机数字表将患者分为观察组及对照组各60例,对照组给予舒利迭雾化吸入治疗,50 mg/250 mg,2次/d,观察组在对照组基础上口服孟鲁司特,10 mg/次,1次/d,疗程为2周。对比分析两组患者治疗效果及治疗前后肺功能及免疫功能的变化。结果观察组总有效率为96.67%,对照组总有效率为76.67%,差异有统计学意义(P<0.05)。观察组患者治疗后第1秒呼吸气体的容积(FEV1)、用力呼吸的肺活量(FVC)及FVC占预计值百分比(FVC%)改善优于对照组(P<0.05)。观察组治疗后白细胞介素4(IL-4)、免疫球蛋白(Ig E)水平、IL-4/INF-γ显著低于对照组,而干扰素(IFN-γ)与对照组相比差异无统计学意义。结论孟鲁司特联合舒利迭能有效改善哮喘急性发作期患者肺功能及免疫功能,提高哮喘患者治疗效果。
Objective To investigate the effect of Montelukast combined with seretide on the efficacy and immune function of patients with acute exacerbation of asthma. Methods From January 2012 to January 2014, 120 patients with acute exacerbation of asthma admitted to our hospital were enrolled in this study. According to the random number table, 60 patients were divided into observation group and control group, while the control group was administered with Seretide Atomization inhalation therapy, 50 mg / 250 mg, 2 times / d, the observation group on the basis of the control group, montelukast, 10 mg / time, 1 / d, course of treatment for 2 weeks. Comparative analysis of two groups of patients with treatment and before and after treatment of lung function and immune function changes. Results The total effective rate was 96.67% in observation group and 76.67% in control group, the difference was statistically significant (P <0.05). The volume of respiratory gas (FEV1), forced vital capacity (FVC) and percentage of predicted FVC (FVC%) in the observation group improved more than the control group (P <0.05). The levels of IL-4, IgE and IL-4 / INF-γ in the observation group were significantly lower than those in the control group, while the levels of IFN-γ in the observation group were significantly lower than those in the control group No statistical significance. Conclusion Montelukast combined with seretide can effectively improve pulmonary function and immune function in patients with acute exacerbation of asthma and improve the therapeutic effect of asthma patients.